Arrowhead Pharmaceuticals
ARWR
61.48
-0.06
-0.10%
Arrowhead Pharmaceuticals
US · ARWR
#1569 by market cap
Listed 1970
61.48
-0.06
-0.10%
Live - 5344 symbols - heartbeat 108s ago
· 2026-10-08 08:29
Pre-market
60.78
-1.14%
After-hours
61.48
0.00%
Overnight
61.48
0.00%
- Market cap
- 8.68B
- P/E (TTM)i
- -26.96
- P/Bi
- 18.65
- EPSi
- -0.01
- Div yieldi
- 0.00%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on ARWR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.2 percentage points.
Institutional ownership
- Held by institutions
- 87.20% -0.19pp
- Institutions
- 584 -3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund59.19%
Hedge Fund16.73%
Public Company4.32%
Individual/Insider3.32%
Sovereign Wealth Fund2.76%
Private Company1.60%
VC/PE Fund1.22%
Government Pension Fund1.00%
Insurance Company0.20%
Other9.67%
Top holders as of 2026-06-30
BlackRock
10.50% · 14.83M sh
Avoro Capital Advisors LLC
8.04% · 11.36M sh
FMR
5.69% · 8.03M sh
Vanguard Capital Management, LLC
4.96% · 7.01M sh
Vanguard Portfolio Management, LLC
4.50% · 6.35M sh
State Street Global Advisors
4.03% · 5.69M sh
Norges Bank Investment Management
2.76% · 3.90M sh
Christopher Anzalone
2.69% · 3.79M sh
Geode Capital Management, LLC
2.50% · 3.53M sh
Fred Alger Management, LLC
2.34% · 3.30M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 12 buys · 37 sells
| Name | Role | Stake |
|---|---|---|
| Christopher Anzalone | Chief Executive Officer | 2.69% |
| Patrick O'Brien | COO, General Counsel & Secretary | 0.24% |
| James Hamilton | Chief of Discovery & Translational Medicine | 0.16% |
| Michael Perry | Lead Independent Director | 0.07% |
| Mauro Ferrari | Independent Director | 0.04% |
| William Waddill | Independent Director | 0.03% |
| Hongbo Lu | Independent Director | 0.03% |
| Adeoye Olukotun | Independent Director | 0.02% |
| Victoria Vakiener | Independent Director | 0.02% |
| Daniel Apel | Chief Financial Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-17 | Adeoye Olukotun | Independent Director | Open Market Disposition | -2,000 | $86.96 |
| 2026-08-17 | Michael Perry | Lead Independent Director | Open Market Disposition | -11,600 | $87.30 |
| 2026-06-14 | Matthew Cohen | Director | Other Acquisition | +11,882 | -- |
| 2026-05-11 | Hongbo Lu | Independent Director | Open Market Disposition | -2,970 | $76.88 |
| 2026-05-11 | Hongbo Lu | Independent Director | Intent to Sell (Form 144) | -315,202 | -- |
| 2026-04-22 | James Hamilton | Chief of Discovery & Translational Medicine | Automatic Disposition | -10,000 | $75.00 |
| 2026-04-22 | James Hamilton | Chief of Discovery & Translational Medicine | Intent to Sell (Form 144) | -10,000 | -- |
| 2026-04-21 | Daniel Apel | Chief Financial Officer | Automatic Disposition | -13,095 | $70.11–71.92 |
| 2026-04-21 | Daniel Apel | Chief Financial Officer | Intent to Sell (Form 144) | -13,095 | -- |
| 2026-03-04 | James Hamilton | Chief of Discovery & Translational Medicine | Automatic Disposition | -10,000 | $64.19 |
| 2026-01-05 | Daniel Apel | Chief Financial Officer | Other Acquisition | +75,000 | -- |
| 2026-01-05 | James Hamilton | Chief of Discovery & Translational Medicine | Other Acquisition | +75,000 | -- |
| 2026-01-05 | Patrick O'Brien | COO, General Counsel & Secretary | Other Acquisition | +75,000 | -- |
| 2026-01-05 | Patrick O'Brien | COO, General Counsel & Secretary | Other Disposition | -2,500 | -- |
| 2026-01-04 | James Hamilton | Chief of Discovery & Translational Medicine | Automatic Disposition | -40,164 | $61.24–68.00 |
| 2026-01-04 | James Hamilton | Chief of Discovery & Translational Medicine | Intent to Sell (Form 144) | -40,164 | $63.10 |
| 2026-01-04 | Patrick O'Brien | COO, General Counsel & Secretary | Automatic Disposition | -49,493 | $61.12–68.00 |
| 2026-01-01 | Christopher Anzalone | Chief Executive Officer | Automatic Disposition | -13,187 | $65.88–66.39 |
| 2025-12-30 | Patrick O'Brien | COO, General Counsel & Secretary | Other Disposition | -2,800 | -- |
| 2025-12-28 | Christopher Anzalone | Chief Executive Officer | Derivative Exercise and Sale | -51,726 | $6.15–69.33 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:29:43 · For reference only, not investment advice and not tailored to your situation.